Family communication of genetic test results among women with inherited breast cancer genes.
communication
family
genetic testing
Journal
Journal of genetic counseling
ISSN: 1573-3599
Titre abrégé: J Genet Couns
Pays: United States
ID NLM: 9206865
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
01
09
2020
received:
28
03
2019
accepted:
07
10
2020
pubmed:
12
11
2020
medline:
16
10
2021
entrez:
11
11
2020
Statut:
ppublish
Résumé
Identification of inherited breast cancer may guide care. These benefits can be amplified through communication of genetic test results with at-risk family members and subsequent family testing (FT). Females with a pathogenic/likely pathogenic (P/LP) variant in BRCA1/2, PALB2, CHEK2, and/or ATM were surveyed about family communication (FC) of genetic test results and FT. Comparisons were made across genes. The 235 participants with P/LP variants (186 BRCA1/2, 28 PALB2, 15 CHEK2, and 6 ATM) had a median age of 54 and most were non-Hispanic whites (89%) with a prior breast cancer diagnosis (61%). When controlling for other variables, FC was higher among younger participants (p<.0001), those with high FC self-efficacy (p=.019), and those with P/LP variants in BRCA1/2 compared to PALB2 (p =.040) and ATM/CHEK2 (p =.032). Higher rates of FC and FT were also observed among female relatives and relatives of closer kinship. Overall 94% of participants would find one or more resources helpful with FC and 70% reported using FC resources when telling family members about their genetic test result. The three most commonly used resources included the following: (a) a family sharing letter (38%); (b) printed materials (30%); and (c) web-based information (23%). Among the 86% who spoke with a genetic counselor (GC), 93% were given at least one FC resource and the three most common resources GCs provided to participants overlapped with the resources participants would find helpful and those that were used. Our results suggest lower FC and FT rates among women with P/LP variants in genes other than BRCA1/2, the reasons for which should be evaluated in future studies. As more data to refine cancer risks and management are generated across these other inherited breast cancer genes, strategies to improve FC and FT are needed to amplify the benefits of genetic testing.
Substances chimiques
Ataxia Telangiectasia Mutated Proteins
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
701-709Subventions
Organisme : NCI NIH HHS
ID : P50 CA098131
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002243
Pays : United States
Informations de copyright
© 2020 National Society of Genetic Counselors.
Références
Alegre, N., Perre, P. V., Bignon, Y. J., Michel, A., Galibert, V., Mophawe, O., & Pujol, P. (2019). Psychosocial and clinical factors of probands impacting intrafamilial disclosure and uptake of genetic testing among families with BRCA1/2 or MMR gene mutations. Psychooncology, 28(8), 1679-1686. https://doi.org/10.1002/pon.5142
Barsevick, A. M., Montgomery, S. V., Ruth, K., Ross, E. A., Egleston, B. L., Bingler, R., Daly, M. B. (2008). Intention to communicate BRCA1/BRCA2 genetic test results to the family. Journal of Family Psychology, 22(2), 303-312. https://doi.org/10.1037/0893-3200.22.2.303
Bednar, E. M., Sun, C. C., McCurdy, S., & Vernon, S. W. (2020). Assessing relatives' readiness for hereditary cancer cascade genetic testing. Genetics in Medicine, 22(4), 719-726. https://doi.org/10.1038/s41436-019-0735-3
Bennette, C. S., Trinidad, S. B., Fullerton, S. M., Patrick, D., Amendola, L., Burke, W., & Veenstra, D. L. (2013). Return of incidental findings in genomic medicine: measuring what patients value-development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genetics in Medicine, 15(11), 873-881. https://doi.org/10.1038/gim.2013.63
Bernstein, J. L., Teraoka, S., Southey, M. C., Jenkins, M. A., Andrulis, I. L., Knight, J. A., & Concannon, P. (2006). Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Human Mutatation, 27(11), 1122-1128. https://doi.org/10.1002/humu.20415
Chopra, I., & Kelly, K. M. (2017). Cancer Risk Information Sharing: The Experience of Individuals Receiving Genetic Counseling for BRCA1/2 Mutations. Journal of Health Communication, 22(2), 143-152. https://doi.org/10.1080/10810730.2016.1258743
Couch, F. J., Shimelis, H., Hu, C., Hart, S. N., Polley, E. C., Na, J., & Dolinsky, J. S. (2017). Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncology, 3(9), 1190-1196. https://doi.org/10.1001/jamaoncol.2017.0424
Cragun, D., Camperlengo, L., Robinson, E., Caldwell, M., Kim, J., Phelan, C., & Pal, T. (2014). Differences in BRCA counseling and testing practices based on ordering provider type. Genetics in Medicine, 17(1), 51-57. https://doi.org/10.1038/gim.2014.75
Cragun, D., Weidner, A., Lewis, C., Bonner, D., Kim, J., Vadaparampil, S. T., & Pal, T. (2017). Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors. Cancer, 123, 2497-2505. https://doi.org/10.1002/cncr.30621
Eijzenga, W., de Geus, E., Aalfs, C., Menko, F., Sijmons, R., de Haes, H., & Smets, E. (2018). How to support cancer genetics counselees in informing at-risk relatives? Lessons from a randomized controlled trial. Patient Education and Counseling, 101(9), 1611-1619. https://doi.org/10.1016/j.pec.2018.05.009
Daly, M., Montgomery, S., Bingler, R., & Ruth, K. (2016). Communicating genetic test results within the family: Is it lost in translation? A survey of relatives in the randomized six-step study. Fam Cancer, 15(4), 697-706. https://doi.org/10.1007/s10689-016-9889-1
Goldgar, D. E., Healey, S., Dowty, J. G., Da Silva, L., Chen, X., Spurdle, A. B., & Chenevix-Trench, G. (2011). Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Research, 13(4), R73. https://doi.org/10.1186/bcr2919
Griffin, N. E., Buchanan, T. R., Smith, S. H., Leon, A. A., Meyer, M. F., Liu, J., & Hagemann, A. R. (2020). Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention. Gynecologic Oncology, 156(1), 140-146. https://doi.org/10.1016/j.ygyno.2019.11.005
Hampel, H. (2016). Genetic counseling and cascade genetic testing in Lynch syndrome. Familial Cancer, 15(3), 423-427. https://doi.org/10.1007/s10689-016-9893-5
Hodgson, J. M., Metcalfe, S. A., Aitken, M., Donath, S. M., Gaff, C. L., Winship, I. M., & Halliday, J. L. (2014). Improving family communication after a new genetic diagnosis: a randomised controlled trial of a genetic counselling intervention. BMC Medical Genetics, 15, 33. https://doi.org/10.1186/1471-2350-15-33
Joshi, A., Kale, S., Chandel, S., & Pal, D. K. (2015). Likert Scale: Explored and Explained. British Journal of Applied Science and Technology, 7(4), 396-403. https://doi.org/10.9734/bjast/2015/14975
Katapodi, M. C., Viassolo, V., Caiata-Zufferey, M., Nikolaidis, C., Buhrer-Landolt, R., Buerki, N., & Chappuis, P. O. (2017). Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol. JMIR Research Protocols, 6(9), e184. https://doi.org/10.2196/resprot.8138
Kurian, A. W., Ward, K. C., Howlader, N., Deapen, D., Hamilton, A. S., Mariotto, A., & Katz, S. J. (2019). Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. Journal of Clinical Oncology, 37(15), 1305-1315. https://doi.org/10.1200/JCO.18.01854
MacDonald, D. J., Sarna, L., van Servellen, G., Bastani, R., Giger, J. N., & Weitzel, J. N. (2007). Selection of family members for communication of cancer risk and barriers to this communication before and after genetic cancer risk assessment. Genetics in Medicine, 9(5), 275-282. https://doi.org/10.1097/GIM.0b013e31804ec075
Mendes, A., Paneque, M., Sousa, L., Clarke, A., & Sequeiros, J. (2016). How communication of genetic information within the family is addressed in genetic counselling: a systematic review of research evidence. European Journal of Human Genetics, 24(3), 315-325. https://doi.org/10.1038/ejhg.2015.174
Menko, F. H., Ter Stege, J. A., van der Kolk, L. E., Jeanson, K. N., Schats, W., Moha, D. A., & Bleiker, E. M. A. (2019). The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice. Familial Cancer, 18(1), 127-135. https://doi.org/10.1007/s10689-018-0089-z
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., … 1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266(5182), 66-71.
Pal, T., Bonner, D., Cragun, D., Monteiro, A. N., Phelan, C., Servais, L., & Vadaparampil, S. T. (2015). A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. Cancer, 123, 4173-4180. https://doi.org/10.1002/cncr.29645
Pal, T., Radford, C., Weidner, A., Tezak, A. L., Cragun, D., & Wiesner, G. L. (2018). The Inherited Cancer Registry (ICARE) Initiative: An Academic-Community Partnership for Patients and Providers. Oncology Issues, 33(6), 54-63. https://doi.org/10.1080/10463356.2018.1525993
Petersen, J., Koptiuch, C., Wu, Y. P., Mooney, R., Elrick, A., Szczotka, K., & Kaphingst, K. A. (2018). Patterns of family communication and preferred resources for sharing information among families with a Lynch syndrome diagnosis. Patient Education and Counseling, 101(11), 2011-2017. https://doi.org/10.1016/j.pec.2018.07.021
Ricker, C. N., Koff, R. B., Qu, C., Culver, J., Sturgeon, D., Kingham, K. E., & Idos, G. E. (2018). Patient communication of cancer genetic test results in a diverse population. Translational Behavioral Medicine, 8(1), 85-94. https://doi.org/10.1093/tbm/ibx010
Roberts, M. C., Dotson, W. D., DeVore, C. S., Bednar, E. M., Bowen, D. J., Ganiats, T. G., & Hampel, H. (2018). Delivery Of Cascade Screening For Hereditary Conditions: A Scoping Review Of The Literature. Health Affairs (Millwood), 37(5), 801-808. https://doi.org/10.1377/hlthaff.2017.1630
Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., & Lindor, N. M. (2015). American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology, 33(31), 3660-3667. https://doi.org/10.1200/JCO.2015.63.0996
Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., & Conte, P. (2017). Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. The New England Journal of Medicine, 377(6), 523-533. https://doi.org/10.1056/NEJMoa1706450
Sharaf, R. N., Myer, P., Stave, C. D., Diamond, L. C., & Ladabaum, U. (2013). Uptake of genetic testing by relatives of lynch syndrome probands: a systematic review. Clinical Gastroenterology and Hepatology, 11(9), 1093-1100. https://doi.org/10.1016/j.cgh.2013.04.044
Witte, K., Cameron, K. A., McKeon, J. K., & Berkowitz, J. M. (1996). Predicting risk behaviors: development and validation of a diagnostic scale. Journal of Health Communication, 1(4), 317-341. https://doi.org/10.1080/108107396127988
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., & Micklem, G. (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature, 378(6559), 789-792.